Documente Academic
Documente Profesional
Documente Cultură
II.
EXPERIMENTAL
Melting points of the synthesized compounds were taken
in open capillary tubes in the Toshniwal electric apparatus and
hence the values reported herein are uncorrected. The IR
spectra of the compounds were recorded in the region 4000400cm-1 range using KBr discs on FTIR 8201 VC Perkin
Elmer Spectrophotometer model 337(USA). 1HNMR and
13
CNMR spectra were recorded on Brucker DRX 200 MHz
spectrometer using CDCl3 as solvent. TMS was used as an
IIa
IIb
IIc
IId
Phthalimidomethyl
Phthalimido--methyl
Phthalimidoethyl
Benzamidomethyl
In Vitro
Dose
% CPE
Inhibition
TI
CT50(g/ml)
EC50(g/ml)
500-4
500
250
2
500-4
500
__
__
500-4
500
125
4
500-4
500
62.5
8
Table I
CT = Cytotoxic, EC = Effective Concentration, TI = Therapeutic Index, CPE = Cytopathic Effect
Compound No.
Dose
IIa
Phthalimidomethyl
Phthalimido--methylmethyl
Phthalimidoethyl
Benzamidomethyl
500-4
IIb
IIc
IId
In Vitro
CT50 (g/ ml)
EC50 (g/ml)
500
125
500-4
500
250
T
I
4
% CPE
Inhibition
10
__
500-4
500
125
4
500-4
500
62.5
8
Table II
CT = Cytotoxic; EC = Effective concentration; TI = Therapeutic index; CPE = Cytopathic effect
Antibacterial Activity8, 9
All the four symmetrical triazines were evaluated for their
antibacterial activity invitro involving broth dilution technique
as recommended by the National Committee for clinical
laboratory standards. The antibacterial activity data are
incorporated in Table III.
Table III
Antibacterial activity data of 2, 2, 2-(1, 3, 5-triazinate-1, 3, 5tri-yl) tris (5-substituted-1, 3, 4-thiadiazoles)
Minimum Inhibitory
Concentration (MIC) IN
Compoun
R
g/ml
d No.
Sf
Kp Ec Pa
Sa
Phthalimidomet
>5
>5
50
25
25
1
hyl
0
0
Phthalimido->5 >5
50
50
50
2
methyl-methyl
0
0
Phthalimidoethy >5
>5 >5
50
25
3
l
0
0
0
Benzamidometh 6.2 6.2
1.5 1.5
25
4
yl
5
5
6
6
20
__
40
50
40
20
REFERENCES
Angeluci, R., Giorn. Mal. Infect. Parasit, 13, 309 (1961)
Chirigos, M. A., Proc. Amer. Assoc. Cancer Res., 3, 310
(1962)
87 | P a g e
[5]
[6]
[7]
[8]
[9]
88 | P a g e